Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a
 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are
 treated with dimethyl fumarate (DMF) as their initial therapy (treatment-naïve), or switching
 from interferon (IFN) or glatiramer acetate (GA) (after suboptimal response defined as
 suboptimal efficacy, intolerance, or poor adherence to IFN or GA), as determined by the
 Prescribing Physician. The secondary objectives of this study in this study population are:
 To assess the impact of DMF over a 12 month period on patient reported outcomes (PROs) and
 health economic related outcomes; and to evaluate additional clinical outcomes at Month 12.
Key Inclusion Criteria:

 -  Have access to the internet and are able to complete online assessments on a computer.

 -  Have relapsing-remitting MS and satisfy the approved therapeutic indication for DMF
 per the Canadian Product Monograph.

 -  Are either treatment-naïve or being treated for RRMS with IFN or GA but, per the
 Prescribing Physician, have a suboptimal response (e.g., suboptimal efficacy,
 intolerance, or poor adherence) to IFN or GA or have stopped treatment with IFN or GA
 for RRMS as a result of suboptimal response within 30-60 days of enrollment.

 Key Exclusion Criteria:

 -  Have major comorbid conditions that would preclude their participation in the study as
 determined by the Prescribing Physician.

 -  Have a history of malignancy. (Patients with basal cell carcinoma that has been
 completely excised prior to study entry remain eligible.)

 -  Are receiving disease modifying therapies other than IFN or GA or have initiated
 treatment with a new disease modifying therapy since discontinuation of IFN or GA.

 NOTE: Other protocol-defined inclusion/exclusion criteria may apply.